The modulatory properties of Si Jun Zi Tang enhancing anticancer of gefitinib by an integrating approach

Publication date: March 2019Source: Biomedicine & Pharmacotherapy, Volume 111Author(s): Chunyu Li, Ming Niu, Ruilin Wang, Xiao wei Zhou, Bin Dong, Shuya Qi, Wei Chen, Mingyu Zhang, Yafei Shi, RuiSheng Li, Guohui LiAbstractLung cancer remains the leading cause of cancer death worldwide, and the current therapy seems to have reached a plateau due to toxicities and acquired resistance. Therefore, exploration of novel therapeutic avenues may be useful. Si Jun Zi Tang (SJZ), a four-herb Chinese medicine formula first described approximately one thousand years, is often prescribed for cancer patients as a complementary therapy. However, whether SJZ benefits cancer patients as well as the main active constituents and its regulatory mechanism in combination with anticancer drugs remains unknown. Here, we investigated the anti-lung cancer potency and underlying mechanisms of the combination of gefitinib plus SJZ in mice with Lewis lung carcinoma (LLC), using histopathology and an integrated strategy of metabolomics and network pharmacology. The results showed that SJZ significantly enhanced gefitinib suppressing tumor growth and inhibiting LLC metastasis in LLC-bearing mice. Furthermore, 9 potential metabolomics biomarkers that differentially expressed in the SJZ/gefitinib group compared to the SJZ group or gefitinib group were identified by untargeted metabolomics, mainly involved three pathways: tricarboxylic acid cycle, tyrosine and tryptophan biosynthesis metabolism and linoleic a...
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research